Di Matteo Berardo, Loibl Markus, Andriolo Luca, Filardo Giuseppe, Zellner Johannes, Koch Matthias, Angele Peter
Berardo Di Matteo, Luca Andriolo, Giuseppe Filardo, I Orthopaedic and Traumatologic Clinic - Biomechanics and Technology Innovation Laboratory, Rizzoli Orthopaedic Institute, 40136 Bologna, Italy.
World J Orthop. 2016 Sep 18;7(9):592-603. doi: 10.5312/wjo.v7.i9.592.
To systematically review the currently available literature concerning the application of biologic agents such as platelet-rich plasma (PRP) and stem cells to promote anterior cruciate ligament (ACL) healing.
A systematic review of the literature was performed on the use of biologic agents (i.e., PRP or stem cells) to favor ACL healing during reconstruction or repair. The following inclusion criteria for relevant articles were used: Clinical reports of any level of evidence, written in English language, on the use of PRP or stem cells during ACL reconstruction/repair. Exclusion criteria were articles written in other languages, reviews, or studies analyzing other applications of PRP/stem cells in knee surgery not related to promoting ACL healing.
The database search identified 394 records that were screened. A total of 23 studies were included in the final analysis: In one paper stem cells were applied for ACL healing, in one paper there was a concomitant application of PRP and stem cells, whereas in the remaining 21 papers PRP was used. Based on the ACL injury pattern, two papers investigated biologic agents in ACL partial tears whereas 21 papers in ACL reconstruction. Looking at the quality of the available literature, 17 out of 21 studies dealing with ACL reconstruction were randomized controlled trials. Both studies on ACL repair were case series.
There is a paucity of clinical trials investigating the role of stem cells in promoting ACL healing both in case of partial and complete tears. The role of PRP is still controversial and the only advantage emerging from the literature is related to a better graft maturation over time, without documenting beneficial effects in terms of clinical outcome, bone-graft integration and prevention of bony tunnel enlargement.
系统回顾目前有关富血小板血浆(PRP)和干细胞等生物制剂应用于促进前交叉韧带(ACL)愈合的文献。
对生物制剂(即PRP或干细胞)在ACL重建或修复过程中促进愈合的应用进行文献系统回顾。对相关文章采用以下纳入标准:任何证据水平的英文临床报告,内容为PRP或干细胞在ACL重建/修复中的应用。排除标准为其他语言撰写的文章、综述或分析PRP/干细胞在膝关节手术中与促进ACL愈合无关的其他应用的研究。
数据库检索共筛选出394条记录。最终分析纳入23项研究:1篇论文应用干细胞促进ACL愈合,1篇论文同时应用了PRP和干细胞,其余21篇论文使用了PRP。根据ACL损伤类型,2篇论文研究了生物制剂在ACL部分撕裂中的应用,21篇论文研究了生物制剂在ACL重建中的应用。从现有文献的质量来看,21项关于ACL重建的研究中有17项为随机对照试验。两项关于ACL修复的研究均为病例系列研究。
在ACL部分和完全撕裂的情况下,研究干细胞促进ACL愈合作用的临床试验较少。PRP的作用仍存在争议,从文献中得出的唯一优势是随着时间推移移植物成熟度更好,但未证明在临床结果、骨移植融合和预防骨隧道扩大方面有有益效果。